Cromatina / Epigenética
Los inhibidores de cromatina/epigenética son compuestos que modulan la estructura y función de la cromatina o interfieren con modificaciones epigenéticas, como la metilación del ADN y la modificación de histonas. Estos inhibidores son herramientas esenciales para estudiar la regulación de la expresión génica y el papel de la epigenética en enfermedades como el cáncer, los trastornos neurológicos y las anomalías del desarrollo. Al dirigirse a los procesos epigenéticos, estos inhibidores pueden alterar los patrones de expresión génica y ofrecer nuevas vías terapéuticas. En CymitQuimica, ofrecemos una amplia selección de inhibidores de cromatina/epigenética de alta calidad para apoyar su investigación en biología molecular, genética y epigenética.
Subcategorías de "Cromatina / Epigenética"
Se han encontrado 2235 productos de "Cromatina / Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Forma y color:SolidPeso molecular:688.74UNC10142
<p>UNC10142 (Compound 44) is a small-molecule antagonist of CHD1, with a binding IC50 value of 1.7 μM. It induces a dose-dependent reduction in the viability of PTEN-deficient prostate cancer cells.</p>Fórmula:C33H52N6O3Forma y color:SolidPeso molecular:580.8HDAC6-IN-56
<p>HDAC6-IN-56 (compound 18d) is an inhibitor of HDAC6, with an IC50 of 1.3 nM. This compound can inhibit the S phase and induce apoptosis in HCT-116 colon cancer cells.</p>Fórmula:C25H27ClN4O4SForma y color:SolidPeso molecular:514.14415TAS-119
CAS:<p>TAS-119 (TAS-2104) is an orally available, selective and potent inhibitor of Aurora A with an IC50 of 1.0 nM.TAS-119 also inhibits Aurora B with an IC50 of 95</p>Fórmula:C23H22Cl2FN5O3Pureza:99.65%Forma y color:SolidPeso molecular:506.36TAT-cyclo-CLLFVY
CAS:<p>Blocks HIF-1α/β dimerization, not HIF-2α; suppresses VEGF, CAIX in cancer cells; antiangiogenic in HUVECs (IC50 = 1.3 μM).</p>Fórmula:C111H188N42O24S2Pureza:98%Forma y color:SolidPeso molecular:2559.1PROTAC SMARCA2/4-degrader-31
CAS:<p>PROTAC SMARCA2/4-degrader-31 (Compound I-280) serves as a degrader for the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF complex. It effectively degrades SMARCA2 in A549 cells and SMARCA4 in MV411 cells, both with a degradation concentration (DC50) of less than 100 nM.</p>Fórmula:C44H51N11O4Forma y color:SolidPeso molecular:797.95AURKA against 1
<p>Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.</p>Fórmula:C28H32FN9O2Forma y color:SolidPeso molecular:545.61HDAC1-IN-9
<p>HDAC1-IN-9 (13c) is an HDAC1 inhibitor. It inhibits the HDAC1 enzyme with an IC50 value of 1.07 µM. This compound exhibits the strongest antiproliferative activity against HT-29 (human colon adenocarcinoma cells), with an IC50 of 1.78 μM. In HCT-116 (human colon cancer cells), HDAC1-IN-9 significantly induces apoptosis. Additionally, HDAC1-IN-9 possesses antiangiogenic properties, reducing the expression levels of VEGFR-2 and phosphorylated VEGFR-2 (pVEGFR-2) by approximately 80%.</p>Fórmula:C17H17N3O3Forma y color:SolidPeso molecular:311.34HDAC-IN-89
<p>HDAC-IN-89 is an inhibitor of HDAC1 (IC50: 0.95 nM), HDAC2 (IC50: 0.86 nM), HDAC3 (IC50: 1.06 nM), and HDAC8 (IC50: 4.24 nM). It can disrupt the cell cycle and induce apoptosis. Additionally, HDAC-IN-89 exhibits antitumor activity.</p>Forma y color:Odour SolidPROTAC BET Degrader-10
CAS:<p>PROTAC BET Degrader-10 targets and degrades BRD4 with a DC50 of 49 nM, using Cereblon ligands.</p>Fórmula:C39H39ClN8O6SForma y color:SolidPeso molecular:783.3MZP-55
CAS:<p>MZP-55 is a selective BRD3/4 degrader based on PROTAC technology(Brd4BD2 with Kd of 8 nM)</p>Fórmula:C57H70ClN7O10SPureza:98%Forma y color:SolidPeso molecular:1080.73PROTAC SMARCA2/4-degrader-27
CAS:<p>PROTAC SMARCA2/4-degrader-27 (PROTAC 2) serves as a targeted degrader, utilizing PROTAC technology to degrade both SMARCA2 and SMARCA4.</p>Fórmula:C49H58FN9O6SForma y color:SolidPeso molecular:920.11CBP/p300-IN-8
CAS:<p>CBP/p300-IN-8 strongly inhibits CBP/P300 bromodomains; CBP IC50=0.01-0.1μM, BRD4 IC50=1-1000μM.</p>Fórmula:C27H31N3O4Forma y color:SolidPeso molecular:461.562PROTAC SMARCA2/4-degrader-26
<p>PROTAC SMARCA2/4-degrader-26 is a PROTAC targeting the SMARCA2/4 proteins. It is composed of the ligand for PROTAC targeting proteins, 2-(4-(3-Amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)acetic acid, an E3 ligase component (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, and a PROTAC linker (S)-2-Amino-3,3-dimethylbutanoic acid. The coupled complex of the E3 ubiquitin ligase ligand + Linker is referred to as (S,R,S)-AHPC.</p>Fórmula:C38H47N9O5SForma y color:SolidPeso molecular:741.9MNK/PIM-IN-1
CAS:<p>MNK/PIM-IN-1 is a novel dual inhibitor targeting both MNK and PIM pathways, characterized by its favorable pharmacokinetic profile.</p>Fórmula:C27H27FN6O2Forma y color:SolidPeso molecular:486.5513β,6α,12β-Dammar-E-20(22)-ene-3,6,12,25-tetraol
CAS:<p>3β,6α,12β-Dammar-E-20(22)-ene-3,6,12,25-tetraol is a compound that functions as a SIRT1 activator, effectively enhancing SIRT1 activity.</p>Fórmula:C30H52O4Forma y color:SolidPeso molecular:476.742HDAC6-IN-53
<p>HDAC6-IN-53 (Compound W28) is an inhibitor targeting histone deacetylase 6 (HDAC6) with an IC50 of 19.65 nM. It reduces the idiopathic pulmonary fibrosis (IPF) phenotype by inhibiting TGF-β1-induced collagen expression and demonstrates therapeutic efficacy in a bleomycin-induced mouse model of pulmonary fibrosis. HDAC6-IN-53 is applicable for research in idiopathic pulmonary fibrosis and related pulmonary fibrotic diseases.</p>Forma y color:Odour SolidGSK8573
CAS:<p>GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).</p>Fórmula:C20H21NO3Pureza:99.81%Forma y color:SolidPeso molecular:323.39CB1R/AMPK modulator 1
<p>Compound 38-S is an orally active CB1R/AMPK modulator with a K i of 0.81 nM and an IC50 of 3.9 nM for CB1R.</p>Fórmula:C25H22Cl2N6O3SPureza:98%Forma y color:SolidPeso molecular:557.45BRD7-IN-1 free base
CAS:<p>BRD7-IN-1, a BI7273 derivative, transforms into PROTAC VZ185 (targets BRD7/9 with 4.5/1.8 nM DC50s) via a VHL linker.</p>Fórmula:C22H26N4O3Pureza:98%Forma y color:SolidPeso molecular:394.47
